NCT07073638View on ClinicalTrials.gov

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

September 15, 2026

Study Completion Date

November 15, 2026

Conditions
Pulmonary Tuberculoses
Interventions
DRUG

RESP30TB

Nitric Oxide agent

DRUG

HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)

isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)

Trial Locations (1)

7531

TASK Clinical Research Centre, Cape Town

All Listed Sponsors
lead

Thirty Respiratory Limited

INDUSTRY